A coalition of 50+ leaders of conservative & free-market orgs signed a letter to members of Congress opposing codifying Pres. Trump’s MFN drug pricing policy model into law, highlighting growing tension between Trump & some of the conservative movement. bit.ly/4qzMwu2

Incubate’s John Stanford & Jef Akst, Managing Editor at BioSpace, expose how recent "regulatory reversals" & inconsistent decision-making are rendering major vaccine & therapeutic programs "uninvestable". They analyze the "Moderna gate" incident. bit.ly/4rnEPs5

One year into Trump’s 2nd term, affordability is up. Gas is at historic lows, while interest and housing costs are falling. Inflation hit 2.7%, while real wages grew 4%, marking the first price decline since 2020. bit.ly/4ariDYf

Last year marked a transformative moment for the biopharmaceutical sector: the industry committed to nearly $500B in domestic investments, an almost 1,500% surge compared to 2024. WWFH documents these investments' flow on our Biopharma Investment Watch. bit.ly/4aXemdW

Reflecting longstanding concerns about possibly discriminatory methodologies, Congress has resisted reliance on QALYs as a determining factor for health care decisions, concerned they & similar metrics may deny for those w/ disabilities & chronic diseases. bit.ly/4bfdX80

The state of the union's better than it was under Pres. Biden. Inflation & gas prices have plummeted, the 2017 tax cuts were extended along with new tax benefits, & regulations slashed more than under any other admin. in recent memory. bit.ly/407jJlW

The U.S. is considering policies that would import overseas pricing & reimbursement for meds from other countries. These foreign countries differ greatly from the U.S. in many ways, & perhaps most fundamentally, in the value they place on disabled lives. bit.ly/4tWI5wi

42 organizations sent a letter urging Congress to eliminate the Center for Medicare & Medicaid Innovation, highlighting that CMMI was created under the ACA w/ a $10B budget each decade to test limited payment models that would reduce costs & improve care. bit.ly/4b6YNR7

In Wyoming, health care choices are often defined by distance, not preference. Physicians and pharmacists know their patients by name and understand the realities of rural life, yet the system around them offers few alternatives when something goes wrong. bit.ly/3NiZNK2

Discriminatory QALY metrics restrict care by valuing "perfect health." These cost-benefit tools deem treatments for people with disabilities less valuable. bit.ly/3NdM4UQ

Nearly everyone agrees drug prices are too high. Patients across LA & the nation struggle with the cost of specialty meds that treat cancer & other serious diseases. While reform is urgently needed, many of the current proposals threaten to make it worse. bit.ly/4unjK33

PRA launched a Hospital Drug Price Finder Tool for consumers to access prescription drug prices in hospitals nationwide. This tool follows a new 3 Axis Advisors report that revealed wide drug price variation across the country and within the same hospital. bit.ly/4cQInyW

The American economy has been built on innovation and a spirit of making things better. That is especially true for the biopharmaceutical sector, where the United States has long led the way in developing lifesaving cures and medications. bit.ly/4scshnM

Pres. Trump will soon welcome Prime Minister Sanae Takaichi to DC for a high-profile U.S.-Japan summit. Given what’s at stake for patients & families on both sides of the Pacific, one issue should rise to the top of the agenda: Japan’s drug pricing system. bit.ly/479x3tW

A policy discussion on Capitol Hill hosted by WWFH examined lessons the US may draw from Europe’s experience w/ pharmaceutical pricing & innovation. As a participant, my key takeaways focused on understanding the trade-offs & broader impact on innovation. bit.ly/3PvWf7Z

Europe once led the world in biopharmaceutical innovation, but lost ground after adopting policies that weakened incentives for R&D and innovation. We must learn from Europe’s experience to preserve our biopharma leadership & access to innovative drugs. bit.ly/4bwFemM

North Carolina's economic success didn't happen by accident. It's the result of decades of policies designed to encourage investment, reward innovation, and allow markets to work. Read full article: bit.ly/4dFzMPO

Lawmakers are considering imposing European-style price controls on prescription drugs. That would cause American biotech companies to lose billions in revenue and inevitably force them to slash research and development budgets. bit.ly/40RYg0P

Europe once led the world in biopharma innovation, but when policymakers shifted priorities to contain rising costs, those drugmakers began looking for better business environments. Now, the US is considering the same policies that led to Europe's decline. bit.ly/4v7Ptps

When I was diagnosed with metastatic breast cancer at 36, my world changed overnight. My focus shifted from my family and career to the terrifying question of whether I was going to live. Then, the next terrifying question: How will I pay for this? bit.ly/47KXLte